Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

New England Journal of Medicine

Volumn 367, Issue 12, 2012, Pages 1087-1097

  Fox, Robert J ^a   Miller, David H ^b   Phillips, J Theodore ^c   Hutchinson, Michael ^d   Havrdova, Eva ^e   Kita, Mariko ^f   Yang, Minhua ^g   Raghupathi, Kartik ^g   Novas, Mark ^g   Sweetser, Marianne T ^g   Viglietta, Vissia ^g   Dawson, Katherine T ^g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e CHARLES UNIVERSITY   (Czech Republic)

^f VIRGINIA MASON MEDICAL CENTER   (United States)

^g BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; CARDIOVASCULAR DISEASE; CELLULITIS; CONTROLLED STUDY; CONVULSION; DEPRESSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; ERYTHEMA; FATIGUE; FEMALE; FLUSHING; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY DISEASE; LEUKOCYTE COUNT; LIVER DISEASE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE STRAIN; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SENSITIVITY ANALYSIS; SIDE EFFECT; SPONTANEOUS ABORTION; THYROID CANCER; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA;

EID: 84866355653     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1206328     Document Type: Article

References (24)

1. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004;251:261-8.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
3. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-92.
4. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation 2010;7:30.
5. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroidderived 2)-like 2 pathway. J Pharmacol Exp Ther 2012;341:274-84.
6. Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M. Dimethyl fumarate suppresses inflammation in vitro via both Nrf2- dependent and Nrf2-independent pathways. Presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, Amsterdam, October 19-22, 2011 (poster). (http://www.posters2view.com/ECTRIMS2011/view. php?nu=227).
7. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med 2001;47:45-50.
8. World Medical Association. WMA Declaration of Helsinki - ethical principles for medical research involving human subjects. November 2010 (http://www.wma.net/en/30publications/10policies/b3/index.html).
9. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-6.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
11. Lublin F, Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-11.
12. Idem. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. Ann Neurol 2001;49:677-81.
13. Papadopoulou A, D'Souza M, Kappos L, Yaldizli O. Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs 2010;19:1603-12.
14. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372:1463-72. [Erratum, Lancet 2009;373:1340.]
15. Kappos L, Gold R, Miller DH, et al. Effect of BG-12 on contrast-enhancing lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler 2012;18:314-21.
16. MacManus DG, Miller DH, Kappos L, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 2011;258:449-56.
17. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107.
18. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-8.
19. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebocontrolled trial. Neurology 1995;45:1268-76.
20. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-8.
21. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol 2011;69:75-82.
22. Copaxone (glatiramer acetate injection) solution for subcutaneous injection. North Wales, PA: Teva Neuroscience, 2009 (package insert).
23. Bista P, Ryan S, Hahm K, et al. Dimethyl fumarate (BG00012) inhibits astrocyte and microglial activation. Mult Scler 2009;15:S132. abstract.
24. Ryan S, Mi S, Hahm K, et al. Dimethyl fumarate inhibits astrogliosis in rodent EAE models. Neurology 2009;72:A379. abstract.